Canton Strategic Holdings is a small, early-stage company with two largely unrelated businesses. Its primary focus, since late 2025, is accumulating Canton Coin (CC) and operating as a "Super Validator" on the Canton Network, a permissioned institutional blockchain built for asset tokenization, settlement, collateral management, and repo transactions. The Canton Network reportedly processes over $6T in tokenized real-world assets and over $350B in daily U.S. Treasury repo. CC is the network's native utility token, used to pay transaction fees, and validators earn CC as rewards for running network infrastructure. Canton Strategic's digital asset model mirrors MicroStrategy's Bitcoin treasury approach: the company raises equity capital and deploys it to buy CC, earns additional CC through validator rewards and staking, and generates returns if CC appreciates as the network grows. Canton Strategic also holds a seat on the Canton Foundation Board, giving it a role in network governance. Separately, through its subsidiary Gravitas, the company is developing two clinical-stage drug candidates: GV104, a buccal film formulation of nalmefene targeting prophylactic opioid protection for military and first responders, with an NDA submission expected in early 2027; and GV023, an oral formulation of infliximab targeting inflammatory conditions like Crohn's disease. Both businesses are pre-revenue. The digital asset strategy is clearly the dominant priority, having absorbed the bulk of capital raised, while Gravitas continues to operate as a secondary subsidiary.